• Livzon Pharmaceutical on Nov. 11, 2026, agreed to buy approximately 0.13% of Xinbeijiang Pharma for RMB 3.85 million.
• The purchase from employee shareholding platform Zhong Hui Yuan will increase its direct stake from approximately 90.64% to 90.77%.
• Internal resources will fund the acquisition, aimed at strengthening control over the active pharmaceutical ingredient subsidiary.
• The connected transaction is exempt from shareholder approval requirements under Hong Kong listing rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livzon Pharmaceutical Group Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261111-12408831), on November 11, 2026, and is solely responsible for the information contained therein.